drugset / Trial / NCT02001909

Effect of Neomycin on the Pharmacokinetics of Regorafenib

NCT02001909

Phase 1 Completed 27 enrolled Bayer
Non-randomizedParallel-groupOpen-label

Summary

To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects

Timeline

Start
2013-12
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Neomycin Unknown 1 g Oral
Subject Regorafenib Small molecule 160 mg Oral

Indications